Innovative recombinant antibodies are produced from the binding domain of heavy-chain-only camelid antibodies, single-domain antibodies (sdAbs), sometimes known as VHH antibodies. Targeting unique epitopes that regular antibodies cannot reach, these antibodies, with their small size of roughly 15kDa and prolonged, structurally different Complementarity Determining Region 3 (CDR3 region), are able. Their small size also contributes to remarkable stability, enabling them to perform effectively across a broader range of temperatures and pH levels compared to conventional antibodies.
ProSci guarantees the generation of excellent single-domain antibodies by using a rigorous methodology. The method starts with the vaccination of proteins expressed in appropriate systems to induce a strong and focused immune response, like mammalian systems for human proteins. Following this, a cDNA library is constructed, and binders are panned in solution to identify those with the desired specificity and affinity.
Each binder undergoes extensive screening to confirm its effectiveness across various applications, including ELISA, histology, and flow cytometry, ensuring reliability and versatility for research and diagnostic needs. ProSci’s advanced techniques and rigorous quality standards make their single-domain antibody production a trusted choice for scientific and medical advancements.
So how are single-domain antibodies detected if they do not have a constant region? ProSci sdAbs are easy to detect with ProSci Cat. No. PM-7669.
Recombinantly produced, sdAbs allow for lot-to-lot reproducibility, maintaining consistency of quality. These antibodies are also easily genetically manipulated and the binding domain can be fused to other scaffolds such as Fc domains.
Contact ProSci if you are interested in engineering the current catalog of ProSci single domain antibodies for your proof-of-concept experiments or licensing opportunities.
Download the single domain antibodies brochure and listen in on the single domain antibody video from ProSci and Biotechniques. These resources give you insight on what a single domain antibody is and how they are becoming hot tools in the field of infectious disease research.
Hear from two experts in the field of single domain antibody development and production, Andy Lee, Lead Scientist of the Single Domain Antibody Program at ProSci Incorporated, and David Eling, Director of Business Development at ProSci Incorporated, on how these unique antibodies are produced and how they are advancing discoveries in research, diagnostic, and therapeutic applications. Listen to the podcast here.
The current catalog of ProSci sdAbs includes antibodies to select immune checkpoint targets and SARS-CoV-2 spike glycoprotein S1 and S2 domains.
